AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.
As we reach the end of 2025, the Indica Labs team extends our sincere thanks to the customers and collaborators who helped make this year one of remarkable innovation, growth, and scientific achievement.
Looking Back: Reviewing 2025 at Indica Labs Read More »
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »
Learn more about how MidAtlantic Permanente Medical Group (MAPMG) used Breast IHC AI deployed in HALO AP® to standardize prognostic scores in newly diagnosed breast cancers and increase diagnostic efficiency of first reads.
HALO AP® and Breast IHC AI at MAPMG Read More »
Check out our flyer to learn more about HALO Clinical AI Solutions
HALO Clinical AI Flyer Read More »
Learn how Kaiser Permanente deployed Breast IHC AI as a laboratory developed test.
Validation and Clinical Implementation of Breast IHC AI Read More »
Read this white paper to learn about the importance of integration and interoperability in digital pathology and explore examples of how flexible solutions like HALO AP® can enhance workflow efficiency and diagnostic accuracy.
HALO AP Integrations Read More »
Learn how this AI-powered tool standardized breast cancer biomarker quantification to include HER2 low and ultralow.
Breast IHC AI Brochure Read More »
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.
